Skip to main content

Table 3 Comparisons of baseline blood biomarker levels between different NSCLC cohorts

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Baseline Biomarker

Cohort A

Cohort B

Cohort C

P-value$

N

Mean (±SD)

N

Mean (±SD)

N

Mean (±SD)

WBC (×103 cells/μL)

27

8.4 (±3.7)

35

7.5 (±2.5)

22

9.2 (±5.3)

0.750

Hemoglobulin (gram/dL)

27

12.5 (±2.0)

35

12.7 (±1.9)

22

12.8 (±1.4)

0.805

Platelet count (× 103 cells/μL)

27

305.2 (±126.6)

35

298.8 (±125.9)

21a

281.0 (±89.8)

0.884

ANC (×103 cells/μL)

27

6.1 (±3.4)

35

5.6 (±2.1)

22

6.9 (±5.1)

0.948

ALCs (×103 cells/μL)

27

1.3 (±0.8)

35

1.1 (±0.6)

22

1.2 (±0.8)

0.571

CD3 + CD4 + %

27

40.6 (±11.1)

35

45.3 (±12.7)

22

44.5 (±9.5)

0.222

CD3 + CD8 + %

27

23.9 (±9.6)

35

27.1 (±12.5)

22

26.4 (±9.5)

0.427

CD3 + %

27

65.7 (±10.3)

35

72.4 (±10.3)

22

72.3 (±8.8)

0.014

CD3 + CD4+ count (cells/μL)

27

512.9 (±282.9)

35

492.3 (±288.1)

22

598.7 (±402.9)

0.793

CD3 + CD8+ count (cells/μL)

27

318.3 (±242.3)

35

305.5 (±260.1)

22

326.7 (±189.0)

0.705

CD4/CD8 ratio

27

2.0 (±0.9)

35

2.1 (±1.3)

22

1.9 (±0.9)

0.934

CD4 plus CD8 count (cells/μL)

27

831.2 (±451.7)

35

797.8 (±431.7)

22

925.4 (±555.5)

0.831

dNLR

27

3.4 (±3.0)

35

3.2 (±1.5)

22

3.4 (±2.5)

0.668

  1. $P-values from Kruskal-Wallis tests. Bold for statistical significance
  2. aOne patient had clumped platelets